Genprex (NASDAQ:GNPX) Posts Earnings Results

Genprex (NASDAQ:GNPX) announced its quarterly earnings data on Friday. The company reported ($9.40) EPS for the quarter, Zacks reports.

Genprex Trading Down 11.3%

GNPX stock opened at $4.32 on Friday. Genprex has a 1-year low of $4.00 and a 1-year high of $1,210.00. The business’s 50 day simple moving average is $9.49 and its 200 day simple moving average is $25.26. The firm has a market capitalization of $2.16 million, a PE ratio of -0.01 and a beta of -0.88.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GNPX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Genprex from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Genprex presently has an average rating of “Sell”.

Hedge Funds Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Susquehanna International Group LLP increased its stake in shares of Genprex (NASDAQ:GNPX) by 11.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 340,056 shares of the company’s stock after buying an additional 35,661 shares during the period. Susquehanna International Group LLP owned 27.20% of Genprex worth $58,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.